



Serial No.: 09/899,780
Attorney Docket No.: 70012590-04
Express Mail Label No.: EL439304318US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor : Gary W. Wood
Serial No. : 09/899,780
Filing Date : July 5, 2001
Title : COMPOSITION AND METHOD OF CANCER ANTIGEN IMMUNOTHERAPY

Group/Art Unit : 1642
Examiner : Not yet assigned
Confirmation No. : 5013

Atty. Docket No. : 70012590-04

TECH CENTER 1600/2900

DEC 26 2001

RECEIVED

H
K
1-5-02

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

NO FEE
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56 and § 1.97(b), the references listed below and on the attached Form PTO/SB/08A (Substitute for Form 1449A-B/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The present application is a divisional of prior application 09/412,681, filed October 5, 1999. Copies of the patents and publications listed on the Form-1449 were previously cited by or submitted to the Office in the prior application (except the one reference marked with footnote, copy enclosed), such that copies of the patents and publications are not required pursuant to 37 C.F.R. § 1.98(d). Submission of these references is not an admission that the references constitute prior art.

(EL439304318US)

Certificate of Mailing by "Express Mail" (37 C.F.R. 1.10)
Express Mail Label No.: EL439304318US

Date of Deposit: December 13, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date indicated above and is addressed to NO FEE, Commissioner for Patents, Washington, D.C. 20231.

Signature: Cynthia R. Maust

Printed Name: Cynthia L. Maust

The Director is hereby authorized to charge any additional amount required, or credit any overpayment, to Deposit Account No. 19-4409.

U.S. PATENTS

<u>Patent No.</u>	<u>Inventor(s)</u>	<u>Issue Date</u>
5,126,132	Rosenberg	06-30-1992
5,290,551	Berd	03-01-1994
5,443,983	Ochoa, <i>et al.</i>	08-22-1995
5,484,596	Hanna, Jr., <i>et al.</i>	01-16-1996
5,637,483	Dranoff, <i>et al.</i>	06-10-1997
5,650,156 ¹	Grinstaff, <i>et al.</i>	07-22-1997
5,679,356	Bonnem, <i>et al.</i>	10-21-1997
5,725,855	Ochoa, <i>et al.</i>	03-10-1998
5,728,388	Terman	03-17-1998
5,766,920	Babbitt, <i>et al.</i>	06-16-1998

FOREIGN PATENTS

<u>Country</u>	<u>Patent No./Publication No.</u>	<u>Publication Date</u>
World	WO 97/05239	02-13-1997

OTHER REFERENCES

1. David N. Liebowitz, M.D., Ph.D., and Carl H. June, M.D., "Recent Advances in Adoptive Immunotherapy," *American Society of Clinical Oncology*, 1092-9118/99:302-312 (1999).
2. Gregory E. Plautz, M.D. *et al.*, "Systemic T Cell Adoptive Immunotherapy of Malignant Gliomas," *J Neurosurg.*, 89:42-51 (1998).
3. Alfred E. Chang and Suyu Shu, "Current Status of Adoptive Immunotherapy of Cancer," *Crit. Rev. Oncol. Hem.*, 22:213-228 (1996).
4. Alfred E. Chang *et al.*, "Adoptive Immunotherapy With Vaccine-Primed Lymph Node Cells Secondarily Activated With Anti-CD3 and Interleukin-2," *J. of Clin. Oncol.*, 15:796-807 (1997).
5. Jan B. Vermorken *et al.*, "Active Specific Immunotherapy for Stage II and Stage III Human Colon Cancer: a Randomised Trial," *The Lancet*, 353:345-350 (1999).

¹ This reference was cited in the International Search Report respecting related PCT Publication No. WO 01/24771 A1, copy enclosed.

6. Alfred E. Change *et al.*, "Clinical Observations on Adoptive Immunotherapy With Vaccine-Primed T-Lymphocytes Secondarily Sensitized to Tumor in Vitro," *Can. Res.*, 53:1043-1050 (1993).

7. Frank P. Holladay *et al.*, "Autologous Tumor Cell Vaccination Combined With Adoptive Cellular Immunotherapy in Patients with Grade III/IV Astrocytoma," *J. Neuro.-Oncol.*, 27:179-189 (1996).

8. Stanley P. L. Leong *et al.*, "Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) and Autologous Melanoma Vaccine Mediate Tumor Regression in Patients with Metastatic Melanoma," *Journal of Immunotherapy*, 22(2):166-174 (1999).

9. Gregory E. Plautz *et al.*, "T-Cell Adoptive Immunotherapy of Metastatic Renal Cell Carcinoma," *Urology*, 54(4):617-624 (1999).

10. Maurizio Bendandi *et al.*, "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma," *Nature Medicine*, 5:1171-1177 (1999).

11. Kruse and Beck, "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours," *Biotechnol. Appl. Biochem.*, 25:197-205 (1997).

Applicant respectfully requests that these references be made of record in the above-identified application and considered by the Examiner during prosecution of the application.

It is respectfully submitted that the present invention as claimed is patentable over the listed references.

This information disclosure statement is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) or before the mailing of a first Office Action on the merits. Accordingly, no fee is due.

Serial No.: 09/899,780
Attorney Docket No.: 70012590-04
Express Mail Label No.: EL439304318US

Acknowledgment of receipt is respectfully requested.

Respectfully submitted,

By:


Lana M. Knedlik, Reg. No. 42,748
STINSON, MAG & FIZZELL, P.C.
1201 Walnut Street, Suite 2800
P.O. Box 419251
Kansas City, MO 64141-6251
Telephone: (816) 842-8600
Facsimile: (816) 691-3495
Attorney for Applicant